

29 April 2022

## ASX ANNOUNCEMENT

### FY22 Outlook Update

**IMEXHS Limited (ASX: IME)** (“IMEXHS” or “the Company”) today updates FY22 guidance and announces measures to improve the Company’s cash position to achieve monthly run rate cash breakeven during 2H FY22.

Trading in Q1 FY22 announced today is encouraging and provides management and the Board with the confidence to provide revenue guidance for the full year, showing strong year-over-year growth. The Q1 FY22 Activity Report highlights the increase in the working capital driven by the significant revenue growth. Management is undertaking projects on two fronts to address the Company’s cash position and runway including reducing costs. These actions are intended to allow the Company to reach profitability and cashflow breakeven.

The first initiative has been to move swiftly to find cost savings that minimise any impact on the Company’s operations and growth plans. This has included some synergies made possible from the acquisition of RIMAB in October 2021. All cost savings initiatives ensure that the integrity of the Company’ 5-year strategic framework announced on 21 March will be maintained. We will continue to invest in product development and sales to maintain the momentum of our disruptive medical imaging software platform and international growth.

The second area of focus is on working capital. A consequence of the company’s growth has been the expansion of working capital on our balance sheet. This is mostly as a result of the growth of radiology services and a slower than acceptable payment cycle. The company is focused on improving working capital levels by taking a more proactive stance on collections and where possible new contract payment terms. After reviewing overdue receivables, we do not believe there are any unprovided credit risks.

Lastly, to align Directors’ interests with shareholders and to contribute to cash preservation, the board has elected to take future directors fees in the form of newly issued shares. Secondly, the board recommends Directors be issued nil paid options equal to 50% of directors’ fees versus 100% in the prior year. The quantum proposed is to ensure adequate headroom for issuance under the executive share plan and to acknowledge the relatively poor share price performance. Both of these measures will be put to shareholders at the AGM on Thursday, 19 May 2022.

The Company updates FY22 guidance as follows (based on a constant currency COP:AUD exchange rate):

- Revenue to be in the range \$19.5m – \$22.0m, up from \$13.4m in FY21
- Underlying EBITDA<sup>1</sup> to be positive for 2022 and up from a loss of \$1.4m in FY21
- Monthly run-rate Underlying cash<sup>2</sup> breakeven to be achieved during 2H FY22

Authorised for release by the Board of IMEXHS Limited.

**-ENDS-**

**For more information, please contact:**

**Media and Investor Relations**

Vanessa Beresford, Citadel-MAGNUS  
[vberesford@citadelmagnus.com](mailto:vberesford@citadelmagnus.com)  
 T: +61 (0)451 422 892

**Business Inquiries**

Reena Minhas, CFO & Company SecretaryE:  
[enquiries@imexhs.com.au](mailto:enquiries@imexhs.com.au)  
 T: +61 (0)438 481 139

**About IMEXHS**

*IMEXHS Limited (ASX: IME) is an innovative provider of medical imaging software and radiology services in 15 countries including Colombia, the US and Australia. Founded in 2012, IMEXHS develops software as a service (SaaS) imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are completely cloud-based, vendor neutral and zero footprint, with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that enhances patient outcomes. For more information, [visit www.imexhs.com](http://www.imexhs.com)*

<sup>1</sup> Underlying EBITDA excludes the impact of FX, share based payments and transactions costs for the RIMAB acquisition in FY21

<sup>2</sup> Underlying cash excludes debt facility proceeds/repayments and RIMAB acquisition related payments